Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy …
AS Correia, N Vale - International Journal of Translational Medicine, 2024 - mdpi.com
Major depressive disorder (MDD), a prevalent mental illness, is marked by a complex
mixture of biological factors. This review focuses on the roles of oxidative stress, tryptophan …
mixture of biological factors. This review focuses on the roles of oxidative stress, tryptophan …
PET/CT study of dopamine transporter (DAT) binding with the triple reuptake inhibitor toludesvenlafaxine in rats and humans
Z Huang, J Wu, Y Guan, Y Wei, F Xie… - European Journal of …, 2024 - Springer
Purpose Toludesvenlafaxine is a recently developed antidepressant that belongs to the
triple reuptake inhibitor class. Despite the in vitro evidence that toludesvenlafaxine inhibits …
triple reuptake inhibitor class. Despite the in vitro evidence that toludesvenlafaxine inhibits …
Optimizing Treatment for Major Depressive Disorder in Adolescents: The Impact of Intradermal Acupuncture-A Randomized Controlled Trial Protocol
N Chen, X Wu, M Tu, S Xiong, J Jin, S Qu… - Neuropsychiatric …, 2023 - Taylor & Francis
Background Major depressive disorder (MDD) exhibits a pronounced occurrence among
adolescents, aligning closely with the lifetime prevalence rate of 16.6% observed in adults. It …
adolescents, aligning closely with the lifetime prevalence rate of 16.6% observed in adults. It …
Atractylenolide I improves behaviors in mice with depression‐like phenotype by modulating neurotransmitter balance via 5‐HT2A
H Pei, R Du, Z He, J Bi, L Zhai… - Phytotherapy Research, 2024 - Wiley Online Library
To explore the antidepressant effects and targets of atractylenolide I (ATR) through a
network pharmacological approach. Relevant targets of ATR and depression analyzed by …
network pharmacological approach. Relevant targets of ATR and depression analyzed by …
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults
S He, Y Yu, J Huang, J Yin, Y Niu, Y Lu… - Therapeutic …, 2023 - journals.sagepub.com
Background: Almost one-third of patients with major depressive disorder (MDD) do not
respond to conventional antidepressants, and new treatments for MDD are urgently needed …
respond to conventional antidepressants, and new treatments for MDD are urgently needed …
[PDF][PDF] Pipeline, novel, and future treatments for unipolar depression
A Sopu - academia.edu
ABSTRACT In 2019, the World Health Organization (WHO) reported that approximately 280
million individuals were living with depression, including 23 million children and …
million individuals were living with depression, including 23 million children and …
[引用][C] TO MARKET, TO MARKET–2022: SMALL MOLECULES
E Araujo, IM Bell, A Burckle, DC Koester… - 2023 Medicinal …, 2023 - ACS Publications